{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.29","value":"-2.0"},{"groupId":"OG001","spread":"6.70","value":"-2.9"},{"groupId":"OG002","spread":"5.72","value":"-2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"77"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.28","value":"-5.8"},{"groupId":"OG001","spread":"5.48","value":"-3.1"},{"groupId":"OG002","spread":"5.96","value":"-4.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"52"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.74","value":"-5.1"},{"groupId":"OG001","spread":"5.64","value":"-4.1"},{"groupId":"OG002","spread":"5.62","value":"-4.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"title":"Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"104"}],"units":"Participants"}],"description":"Clinically relevant threshold (at any time point). Reduction of ≥ 5%, Reduction of ≥ 10%","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \\< 1500 μg /day.","id":"OG000","title":"Pasireotide 600 μg"},{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day","id":"OG001","title":"Pasireotide 900 μg"},{"description":"Patients received pasireotide 600 μg or 900 μg BID","id":"OG002","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Number of patients with available data differed at visits","reportingStatus":"POSTED","timeFrame":"Baseline, week 12, 24 and 48","title":"Percent Change in Cushing's Disease Clinical Signs and Symptoms - Waist Circumference","type":"SECONDARY","unitOfMeasure":"percent change of centimeters"}